Vyome Holdings, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2025-11-14 | -0.11 | -3.12 | -2736.36% |
| 2025-11-13 | — | — | — |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| HIND | +19.39% | -25.24% | -31.98% | -88.09% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +16.42% | -20.60% | -28.53% | -100.77% |